During the GLP-1 shortage, many people got semaglutide from compounding pharmacies instead of as Ozempic or Wegovy. That was possible because of a special rule for drugs in short supply. The shortage is now over, and that changes things. Here is what is different and what to ask if you are using, or thinking about, a compounded version.
Why compounded copies were allowed
Compounding is when a pharmacy mixes a medicine for a specific patient. It has real uses, such as making a version without an ingredient someone is allergic to. Federal law generally does not let pharmacies make routine copies of an FDA-approved drug. One big exception is when the drug is on FDA’s shortage list.
Semaglutide and tirzepatide were both in shortage for a long time. That opened the door for compounded copies, and many telehealth programs offered them.
What changed when the shortage ended
FDA declared the tirzepatide shortage resolved on December 19, 2024. It declared the semaglutide shortage resolved on February 21, 2025. FDA gave compounders a short grace period to wind down, and those grace periods have ended.
Now the normal rules apply again. In plain terms:
- Pharmacies (503A): They can compound for individual patients with a prescription, but they cannot regularly make copies of an approved drug. A prescriber can document that a patient needs a meaningful change, such as leaving out an ingredient they react to. That’s different from a copy.
- Outsourcing facilities (503B): These larger operations face tighter limits on using bulk semaglutide or tirzepatide now that the drugs are no longer in shortage.
FDA also issued an import alert in 2025 aimed at GLP-1 ingredients from unverified foreign sources. That makes it harder for questionable raw material to enter the country.
What FDA has seen with compounded GLP-1s
FDA has shared concerns about unapproved GLP-1 products. These include dosing mistakes when people measure their own doses, products that were not kept cold during shipping, and labels that make false claims. Some products have listed pharmacies that do not exist. FDA has received adverse event reports linked to both compounded semaglutide and compounded tirzepatide.
Questions to ask if you use a compounded version
- Is this pharmacy state-licensed, and where is it located?
- Why is a compounded version right for me instead of an approved product?
- How will my dose be measured, and who can I call with questions?
- How should it be shipped and stored?
- What should I do if my supply changes or stops?
If a program cannot answer these clearly, that is a reason to pause. Your pharmacist is a good, free resource here. Also ask your prescriber whether an approved option, including a pill form, could work for you.
The bottom line
The shortage was the main reason compounded semaglutide was so easy to find. That reason is gone. Compounded versions can still exist in narrow cases, but they are not FDA-approved. Talk with your prescriber and pharmacist before starting, switching or stopping any GLP-1.